Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid

Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

(2015) Damayanthi Devineni et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects

(2015) Charles D. Meyers et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome

(2015) Charles Daniel Meyers et al.   Lipids in Health and Disease

Pharmacokinetic and pharmacodynamic drug-drug interaction assessment between pradigastat and digoxin or warfarin

(2014) Jing-He Yan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The DGAT1 inhibitor Pradigastat Decreases Chylomicron Secretion and Prevents Postprandial Triglyceride Elevation in Humans

(2013) Charles Daniel Meyers et al.   Journal of Clinical Lipidology

Pharmacokinetics and Tolerability of Oseltamivir Combined with Probenecid

(2008) M. Holodniy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects

(2008) Marian Iwamoto et al.   CLINICAL INFECTIOUS DISEASES

Acylation of Acylglycerols by Acyl Coenzyme A:Diacylglycerol Acyltransferase 1 (DGAT1)

(2008) Dong Cheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY